Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias.

Sotalol, a class III antiarrhythmic agent, is used to maintain sinus rhythm in patients with atrial fibrillation or atrial flutter (AFIB/AFL). Despite its efficacy, sotalol's use is limited by its potential to cause life-threatening ventricular arrhythmias due to QT interval prolongation. Traditionally, sotalol administration required hospitalization to monitor these risks.

A GPU-accelerated fuzzy method for real-time CT volume filtering.

During acquisition and reconstruction, medical images may become noisy and lose diagnostic quality. In the case of CT scans, obtaining less noisy images results in a higher radiation dose being administered to the patient. Filtering techniques can be utilized to reduce radiation without losing diagnosis capabilities.

Development of Novel Squid Gladius Biomaterials for Cornea Tissue Engineering.

Cornea tissue engineering is strictly dependent on the development of biomaterials that fulfill the strict biocompatibility, biomechanical, and optical requirements of this organ. In this work, we generated novel biomaterials from the squid gladius (SG), and their application in cornea tissue engineering was evaluated. Results revealed that the native SG (N-SG) was biocompatible in laboratory animals, although a local inflammatory reaction was driven by the material.

Development of Variable Charge Cationic Hydrogel Particles with Potential Application in the Removal of Amoxicillin and Sulfamethoxazole from Water.

Cationic hydrogel particles (CHPs) crosslinked with glutaraldehyde were synthesized and characterized to evaluate their removal capacity for two globally consumed antibiotics: amoxicillin and sulfamethoxazole. The obtained material was characterized by FTIR, SEM, and TGA, confirming effective crosslinking. The optimal working pH was determined to be 6.

[Position statement on the use of amlodipine during pregnancy. Working Group on Hypertension in Women, Argentine Society of Hypertension].

Pharmacological management of HDP includes agents supported by extensive evidence ensuring their safety for use. Among those traditionally described in the literature are: alpha-methyldopa, labetalol, and sustained-release nifedipine (NIF-RETARD). These drugs, in addition to being compatible with pregnancy, present additional eligibility criteria.